Local Lung Targeting of Tumor Associated Macrophages Combined with  Cytoreductive Therapy Decrease Tumor Burden in a Secondary Lung Cancer Model by Alhudaithi, Sulaiman et al.
Virginia Commonwealth University 
VCU Scholars Compass 
Graduate Research Posters Graduate School 
2020 
Local Lung Targeting of Tumor Associated Macrophages 
Combined with Cytoreductive Therapy Decrease Tumor Burden in 
a Secondary Lung Cancer Model 
Sulaiman Alhudaithi 
Virginia Commonwealth University 
Hanming Zhang 
Rashed Almuqbil 
See next page for additional authors 
Follow this and additional works at: https://scholarscompass.vcu.edu/gradposters 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Downloaded from 
Alhudaithi, Sulaiman; Zhang, Hanming; Almuqbil, Rashed; Du, Wei; Sunbul, Fatemah; Bos, Paula; and da 
Rocha, Sandro, "Local Lung Targeting of Tumor Associated Macrophages Combined with Cytoreductive 
Therapy Decrease Tumor Burden in a Secondary Lung Cancer Model" (2020). Graduate Research Posters. 
Poster 75. 
https://scholarscompass.vcu.edu/gradposters/75 
This Poster is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has 
been accepted for inclusion in Graduate Research Posters by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
Authors 
Sulaiman Alhudaithi, Hanming Zhang, Rashed Almuqbil, Wei Du, Fatemah Sunbul, Paula Bos, and Sandro 
da Rocha 
This poster is available at VCU Scholars Compass: https://scholarscompass.vcu.edu/gradposters/75 
Results: Effect of Immunochemotherapy on Tumor Burden and Tumor Microenvironment (TME)
• Local administration of immunotherapy to the lungs 
(PLX p.a.) supports chemotherapy (PTX i.v.) of breast 
to lung metastases:
Lung cancer is the leading cause of cancer death among both men
and women in the US and worldwide.1 In spite of recent advances in
the treatment of lung cancer including targeted and antibody
therapies, 5 year overall survival of lung cancer patients continues to
be very low at ca. 19%.2 The purpose of this work was to evaluate the
efficacy of a locally administered small molecule colony stimulating
factor 1 receptor inhibitor (CSF-1Ri), PLX3397 (PLX), alone or in
combination with cytoreductive therapy (paclitaxel, PTX) in reducing
the tumor burden of an in vivo model of secondary lung cancer. CSF-
1Ri have been shown to inhibit M2-like (tumorigenic) tumor-
associated macrophages (TAMs or M2 Mɸ), and alone or in
combination with chemotherapies, to reduce tumor burden in pre-
clinical and clinical studies of various types of primary and secondary
cancers.3,4 Local administration of immunotherapy to the lungs may
enhance lung biodistribution of such therapies, and reduce potential
unwanted off-target toxicity. In addition, combination of such therapy
with low dose standard of care chemotherapy may offer improved
anti-tumor effects.
• Treatment: 
 Control: vehicle i.t. 
 Immunotherapy: PLX i.t.
 Chemotherapy: PTX i.v.
 Combination: PLX i.t. 
+ PTX i.v. 
 Pre-clinical Model of Secondary Lung Cancer
DPI: day post tumor implantation
IVIS: in vivo imaging system
Terminal day: day 19
Vehicle: 1% DMSO, 5%Tween80 in PBS
Pulmonary administration (p.a.): 
intratracheal installation (i.t.)  
Methods
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 Combination Immunochemotherapy: Efficacious and Safe 
• Tumor Burden (n=9-10):
 PLX or PTX  decreased burden (weight)
 PLX + PTX   additive effect  further  
reduction in tumor burden
• Toxicity:
 All treatment groups  no severe toxicity    
as per body weight, fur appearance, 
movement, staining around eye/nostrils, 
respiration, behavior.
CSF-1R  M2-like Mɸ reduction
pCSF-1R  tumorigenic response 
 PLX 
PTX negatively affects TME  increases CSF-1R and pCSF  M2 Mɸ recruitment?
 PLX + PTX
 PLX p.a.: Reaches its Molecular Target in TME
Conclusions
 PLX p.a.: Decreases M2-like Macrophages in TME
 4T1 Transduced and no Changes in Response to PTX
 PTX induced cell kill in WT 4T1 and  
4T1 Luc TdT cells  transduced cells 
behave as WT 
n=3-4 n=3-4
Background and Purpose
• Western Blot: 
• MTT Assay: 
 Transduction w/ Lentivirus expresses 
luciferase (Luc), TdTomato (TdT), & 
puromycin resistant gene  >99% TdT
• 4T1 Transduction: 
WT 4T1 4T1 Luc TdT
all @ 1 mg/kg 
 PLX + PTX reduced tumor burden (ex vivo IVIS & lung weight)
 PLX reached its molecular target, Mɸ in TME
 PLX reduced M2 Mɸ  shifted the balance towards
anti-tumorigenic Mɸ phenotype
 PLX  downregulated (CD11b+) F480+CD206+ M2 Mɸ
 PLX + PTX  downregulated F480+CD206+  M2 Mɸ
 PTX  no effect on M2 Mɸ   
All therapeutics  no effect on total Mɸ
• Immunofluorescence and Flow Cytometry: 
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